SARS-CoV-2 antigen rapid tests and universal screening for COVID-19 Omicron variant among hospitalized children

Am J Infect Control. 2023 Mar;51(3):255-260. doi: 10.1016/j.ajic.2022.11.002. Epub 2022 Nov 9.

Abstract

Background: Clinical utility of universal antigen rapid test (ART) in the pediatric setting is unknown. We aimed to assess the performance and utility of universal ART in hospitalized children (≥5-year-old) to prevent nosocomial COVID-19 transmission.

Methods: Cross-sectional study involving all hospitalized pediatric patients aged ≥5-year-old from 2 periods during Omicron wave. Clinical data, ART and polymerase chain reaction test results were collected.

Results: A total of 444 patients were included from the 2 study periods, and 416 patients (93.7%) had concordant results between ART and polymerase chain reaction. The overall sensitivity and specificity of ART were 83.3% (95% CI: 75.2-89.3) and 97.5% (95% CI: 95.0-98.8), respectively. Negative predictive values of ART between the Omicron emergence and Omicron peak periods for a probable case group were 71.4% and 66.7%, respectively, and for a suspect case group 91.4% and 75.0%, respectively. Negative predictive values for an unlikely case group was >95% in both periods. Positive predictive value of ART was >85% for probable and suspect case groups in both periods. Seventy-five percent of patients (n = 15) who were incorrectly classified as SARS-CoV-2 negative by ART had potentially viable virus. No large nosocomial transmission clusters were detected.

Conclusions: Universal ART screening may limit nosocomial outbreaks in hospitalized children. The performance can be optimized by considering clinical symptoms, exposure and periods within COVID waves.

Keywords: Coronavirus disease 2019; Sensitivity; Severe acute respiratory syndrome coronavirus 2; Specificity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Testing
  • COVID-19* / diagnosis
  • Child
  • Child, Hospitalized
  • Child, Preschool
  • Cross Infection*
  • Cross-Sectional Studies
  • Humans
  • SARS-CoV-2

Supplementary concepts

  • SARS-CoV-2 variants